See more : Vu1 Corporation (VUOC) Income Statement Analysis – Financial Results
Complete financial analysis of Personalis, Inc. (PSNL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Personalis, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Mutual Federal Bancorp, Inc. (MFDB) Income Statement Analysis – Financial Results
- Oriental Payment Group Holdings Limited (8613.HK) Income Statement Analysis – Financial Results
- Libero Copper & Gold Corporation (LBCMF) Income Statement Analysis – Financial Results
- Pingify International Inc. (PGFY) Income Statement Analysis – Financial Results
- Wiscom System Co., Ltd. (002090.SZ) Income Statement Analysis – Financial Results
Personalis, Inc. (PSNL)
About Personalis, Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 73.48M | 65.05M | 85.49M | 78.65M | 65.21M | 37.77M | 9.39M |
| Cost of Revenue | 55.27M | 51.70M | 53.84M | 58.53M | 43.13M | 25.97M | 11.74M |
| Gross Profit | 18.21M | 13.35M | 31.66M | 20.11M | 22.08M | 11.81M | -2.34M |
| Gross Profit Ratio | 24.78% | 20.52% | 37.03% | 25.57% | 33.86% | 31.25% | -24.94% |
| Research & Development | 64.78M | 64.91M | 49.31M | 28.57M | 22.42M | 14.30M | 9.92M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.27M | 9.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.73M | 63.97M | 47.70M | 33.69M | 22.08M | 11.27M | 9.90M |
| Other Expenses | 13.64M | 61.00K | -42.00K | -24.00K | -1.44M | -33.00K | -227.00K |
| Operating Expenses | 128.14M | 128.88M | 97.01M | 62.26M | 44.50M | 25.58M | 19.82M |
| Cost & Expenses | 183.42M | 180.58M | 150.85M | 120.79M | 87.63M | 51.54M | 31.56M |
| Interest Income | 5.90M | 2.40M | 367.00K | 949.00K | 1.62M | 293.00K | 100.00K |
| Interest Expense | 110.00K | 201.00K | 184.00K | 2.00K | 1.13M | 1.89M | 1.30M |
| Depreciation & Amortization | 11.30M | 12.88M | 8.96M | 7.17M | 5.73M | 3.07M | 1.22M |
| EBITDA | -96.81M | -104.64M | -59.01M | -34.05M | -18.21M | -14.92M | -21.07M |
| EBITDA Ratio | -131.74% | -173.83% | -76.06% | -45.09% | -34.10% | -27.65% | -224.36% |
| Operating Income | -109.94M | -115.53M | -65.35M | -42.15M | -22.42M | -13.77M | -22.16M |
| Operating Income Ratio | -149.61% | -177.61% | -76.44% | -53.59% | -34.38% | -36.45% | -235.95% |
| Total Other Income/Expenses | 1.72M | 2.26M | 141.00K | 923.00K | -2.66M | -6.11M | -1.43M |
| Income Before Tax | -108.21M | -113.28M | -65.21M | -41.22M | -25.08M | -19.88M | -23.59M |
| Income Before Tax Ratio | -147.27% | -174.14% | -76.28% | -52.41% | -38.45% | -52.63% | -251.18% |
| Income Tax Expense | 83.00K | 40.00K | 14.00K | 57.00K | 9.00K | 7.00K | 5.00K |
| Net Income | -108.30M | -113.32M | -65.23M | -41.28M | -25.08M | -19.89M | -23.60M |
| Net Income Ratio | -147.38% | -174.20% | -76.29% | -52.49% | -38.47% | -52.64% | -251.23% |
| EPS | -2.25 | -2.48 | -1.49 | -1.06 | -0.80 | -0.91 | -1.08 |
| EPS Diluted | -2.25 | -2.48 | -1.49 | -1.06 | -0.80 | -0.91 | -1.08 |
| Weighted Avg Shares Out | 48.18M | 45.70M | 43.89M | 39.11M | 31.24M | 21.75M | 21.75M |
| Weighted Avg Shares Out (Dil) | 48.18M | 45.70M | 43.89M | 39.11M | 31.24M | 21.75M | 21.75M |
Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer
Why Personalis Stock Dropped Today
Personalis Announces Pricing of Public Offering of Common Stock
Personalis Announces Launch of Public Offering of Common Stock
Personalis Reports Preliminary Fourth Quarter 2020 Revenue
Personalis Reports Preliminary Fourth Quarter 2020 Revenue
Personalis to Present at the 23rd Annual Needham Virtual Growth Conference
Liquid Biopsy Cancer Testing Is The Next Big Investment Opportunity
Personalis' (PSNL) CEO John West on Q3 2020 Results - Earnings Call Transcript
Personalis to Participate in Upcoming Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports